Use of DPP‐4 inhibitors decreased in incident patients over time in those with high ASCVD risk (p < 0.05), but did not exhibit a statistically significant monotonic trend in patients with ASCVD (p‐value 0.47) and HF (p = 0.11) (Figure 3). This evidence concerns the gene DPP4 and atherosclerosis.